cd22 car-transduced t cells
Precursor B-Cell Acute Lymphoblastic Leukemia
Explore 24 assets in Precursor B-Cell Acute Lymphoblastic Leukemia →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
39Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05442515CT.gov CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | — | Recruiting | — | — | — |
NCT02315612CT.gov Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Precursor B-Cell Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cd22 car-transduced t cells (this asset) | National Cancer Institute (NCI) | P1 | CCC · 53 |
| Blinatumomab | Amgen | P3 | BBB |
| Fludarabine | National Cancer Institute (NCI) | P2/3 | BB |
| Cyclophosphamide | Princess Maxima Center for Pediatric Oncology | P2/3 | BB |
| Cytarabine | Princess Maxima Center for Pediatric Oncology | P2 | B |
| Olverembatinib | First Affiliated Hospital of Zhejiang University | P2 | B |
| Pegaspargase | First Affiliated Hospital of Zhejiang University | P2 | B |
| Methotrexate | First Affiliated Hospital of Zhejiang University | P2 | B |
| Dexasone | Princess Maxima Center for Pediatric Oncology | P2 | B |
+19 more in the Precursor B-Cell Acute Lymphoblastic Leukemia cohort
Other indications for cd22 car-transduced t cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Adult Acute Lymphocytic Leukemia | — | P2 | BB · 64 |
| B-Cell Acute Lymphoblastic Leukemia | — | P2 | B · 62 |
| B-Cell Non-Hodgkin Lymphoma | — | P1/2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. cd22 car-transduced t cells in Precursor B-Cell Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd22-car-transduced-t-cells-precursor-b-cell-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →